Navigation Links
Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
Date:12/14/2009

erty protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize ovarian cancer diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop ovarian cancer diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future ovarian cancer diagnostic products; (5) uncertainty of market acceptance of its OVA1 diagnostic test or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (6) uncertainty that Vermillion will successfully license or otherwise successfully partner its products; (7) uncertainty that Vermillion will have the resources to successfully complete its bankruptcy reorganization; (8) uncertainty as to whether operating under Chapter 11 may harm our business; (9) uncertainty regarding whether we will be able to obtain confirmation of a Chapter 11 plan of reorganization; (10) uncertainty as to whether we will be able to emerge from bankruptcy without being liquidated or obtain the necessarily funding to continue as a going concern; (11) uncertainty whether a plan of reorganization may result in holders of our common stock receiving no or limited distributions on account of their interests and cancellation of their common stock; (12) uncertainty whether operating under the U.S. Bankruptcy Code may restrict our ability to pursue our business strategies and identify and develop additional diagnostic products; (13) uncertainty whether the trading in our stock will become significantly less liquid or our ability to relist on shares on the Nasdaq Global Sele
'/>"/>
SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 LayerBio, Inc., an MIT spinoff ... first round of seed financing from friends and family ... to develop a novel sustained-release product for ophthalmology. , ... and their commitment to this important work," said Dr. ... one of many areas in which innovations in drug ...
(Date:7/29/2014)... technologists have hurdled a number of significant technological ... revolutionary observing technology originally created for the James ... Principal Investigator Harvey Moseley, a scientist at NASA,s ... demonstrated that electrostatically actuated microshutter arrays that ... are as functional as the current technology,s ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... a new way of manufacturing microstructured surfaces that ... self-assembly of carbon nanotubes, could exhibit a variety ... and strength, or the ability to repel water ... that mechanical forces can be used to direct ... we can independently control the mechanical properties ...
Breaking Biology Technology:Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2
... WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology and ... in China and the United,States, today announced that ... Vice,President of Strategy., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Yu worked at Pfizer Inc., where,she co-led Pfizer,s ...
... Archi-Tech Systems, a,leading provider of pharmaceutical ... PromoTrack, a new solution custom-designed to,rapidly measure ... promotions. Archi-Tech has tailored its proven DART ... marketers, seamlessly,integrating disparate promotional campaign and Rx ...
... Inc.,(TSX: SDI) today announced that it has entered ... Medical for Spectral,s Endotoxin,Activity Assay (EAA(TM)), the only ... the terms of the agreement, BB Medical will ... "BB Medical is a leading distributor of medical ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy 2Pharmaceutical Marketing Done Right: Archi-Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management 2Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay 2
(Date:7/29/2014)... parents of preterm babies latest research from the ... become teenagers, the brains of many preterm children can perform ... study conducted by the University,s Robinson Research Institute ... no brain injury in early life, their cognitive abilities as ... peers. , However, the results of the study, published in ...
(Date:7/28/2014)... approved by the U.S. Food and Drug Administration (FDA) ... certain bacterial pathogens inside human cells, including those that ... findings, published in mBio , the online open-access ... new way of identifying non-antibiotic drugs that could one ... of drugs on the list inhibit the growth of ...
(Date:7/28/2014)... Ariz. - Reactions among minerals and organic compounds in ... carbon cycle, they provide energy for the deep biosphere, ... However, very little is known about how minerals influence ... State University have demonstrated how a common mineral acts ... negating the need for toxic solvents or expensive reagents. ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... for Research in Vision and Ophthalmology (ARVO) is pleased ... recipients will be acknowledged at the ARVO 2012 Annual ... Proctor Medal: Peter Sterling, PhD, Mildred Weisenfeld Award ... FARVO, Cogan Award: Jeffrey L. Goldberg, MD, PhD, Friedenwald ...
... AMHERST, Mass. A team of kinesiology researchers led ... Amherst recently received a 2.5-year, $975,000 grant through the ... to study how the average 100-lb. equipment load carried ... missions, affects their survivability, likelihood of injury and ability ...
... Md. - The first Maryland municipality to earn a ... is the Town of Berlin on the Eastern Shore. ... by the University of Maryland,s Environmental Finance Center - ... as well as revitalize and improve their long-term quality ...
Cached Biology News:2012 ARVO Award recipients honored at annual meeting 2Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2Maryland gets its first 'Certified Sustainable' community: Berlin 2
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
... Removal , , Removes ... cross-reactivity with other proteins , Simple, just ... Economical new surface technology, not based on ... with protein analysis. SurfactAway offers a simple ...
... SDS and Non-ionic Detergent Removal ... , Very selective, virtually no cross-reactivity with ... and discard pellet , Economical new ... , Detergents can often interfere with protein ...
... 3000 workstation automates a wide array of ... Proteomic Sample Preparation to Bio-Molecular and Cell ... of the Caliper Sciclone enables numerous combinations ... meet the needs of a given application, ...
Biology Products: